Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 11/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 10/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CASR | P41180 | 2/20 | 0.32 |
| ▸ | PLAU | P00749 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5582041 | 0.91 | DPP4 (0.33) | PTGESPTGS2TDP1 | |
| SCHEMBL5581764 | 0.82 | TDP1 (0.36) | TDP1CASRPLAU | |
| SCHEMBL5581769 | 0.82 | TDP1 (0.36) | TDP1CASR | |
| SCHEMBL5582159 | 0.81 | TDP1 (0.38) | TDP1 | |
| SCHEMBL5581855 | 0.81 | RXFP1 (0.33) | TDP1 | |
| SCHEMBL5582222 | 0.79 | KDM4E (0.40) | PTGESPTGS2 | |
| SCHEMBL5582072 | 0.78 | CCNC (0.37) | TDP1 | |
| SCHEMBL5581874 | 0.75 | ADORA1 (0.43) | — | |
| SCHEMBL5582308 | 0.75 | MEN1 (0.38) | — | |
| SCHEMBL5581661 | 0.72 | ADORA1 (0.44) | PTGESPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225308-A1 | 2-Amino Quinazoline Derivative | KYOWA HAKKO KOGYO CO.,LTD. (JP) | 2007-09-27 | — | — | US | disclosed |
| EP-1726584-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225308-A1 | 2-Amino Quinazoline Derivative | AGTR2, ABL1, AGTR1 | PTGES 4676/4885PTGS2 2985/4885TDP1 2572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.